An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...
Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...
Hosted on MSN
Roche says experimental drug helped slow disability in progressive multiple sclerosis study
Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib. Fenebrutinib is an ...
Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results